上海招聘

? Ensures team delivers clinical supplies effectively and consistently, balancing cost and risk to supply

? Ensures expert input and support from cross functional groups

? Ensures effective communication with customers and partners. Identify with proactive mitigation of risks threatening quality or delivery of supplies. Escalate significant issues as appropriate

? Understands clinical study protocol requirements into demands for drug product within a clinical study including requirements for placebo and comparators. Author the drug supply section of Clinical Study Protocol and lead development of master label text

? Use simulation tools and supply chain expertise to design optimised, lean supply chains for individual studies, defining allocation of contingency stock, (IVRS parameters) and requirements of drug product. Where possible seek innovative flexible supply chain solutions capable of supporting multiple studies

? Using this information, develop options for how the supply requirements of individual/groups of clinical studies can be delivered and propose to the project team. This will include sourcing (in or out) and alignment of sourcing activities with customers, detailed plans including timing of investments/cost expenditure (e.g. purchase of comparator product, phased spend at CROs), identification and management of risks

? Produce a (Study Drug Packaging Agreement) documenting the agreed supply option providing details of the design, set-up and how the supply chain will operate for each study/group of studies

? Ensure supply chain input into the design of the random scheme, incl. pack lists and timely provision of these to Delivery or CRO

? Collaborate with CRO partners in development of pack design and review the technical part of the outsourcing contract. Review changes to the contract with CRO partners and Sourcing Managers as necessary

? Establish the supply chain for individual/groups of studies and ensure delivery of the end to end supply of materials to meet study needs

? Monitor the performance of the supply chain and optimise for higher volume phases of the project, balancing speed, quality and cost with respect to the agreed level of risk

? Understands GMP (Good Manufacturing Practise) and the impact it has on supply chain activities

? Monitor the budget for individual study supply activities and materials for the project.

? Maintain appropriate information for study supply activities

? Manage change in demand and supply, resolve issues, escalating when appropriate

? Proactively manage study close out activities, including stock destruction and archiving

? Work with other Study Managers to resolve issues, share best practice and continually develop competence

任职要求：

? Experiences in supply chain related or drug development discipline or equivalent qualification

? Experience of demand planning and forecasting

? A signi？cant background in project managing and in？uencing customer demands

? Awareness of GMP (Good Manufacturing Practise)

? Strong in？uencing, negotiating and problem-solving skills, across geographical and cultural boundaries

? Risk identification and management

? Excellent English written and verbal communication skills

? Preferred Experience, Functional Knowledge, Business Knowledge, Education, Specialist Skills

? Extensive experience of managing supply chain activities and demand planning

? Working knowledge of the Clinical Trial Directive and global regulatory environment impacting the provision of investigational products

? In depth knowledge of R&D supply chain and drug development process

? In depth knowledge of Clinical Development processes relevant to the supply of clinical materials

? Experience of project management

    迪哲医药的前身为阿斯利康亚洲及新兴市场创新研发中心，设立于中国上海，是阿斯利康全球四个研发中心之一（另三个中心分别位于英国剑桥、瑞典哥德堡、美国盖瑟斯堡）；是国际一流、高产出的创新药研发机构，拥有全球领先的转化医学和新药分子设计与筛选技术平台；在恶性肿瘤、自身免疫性疾病、肾病等重大疾病的新药研究方面积累了丰富经验。
    迪哲医药，于2017年10月独立运营，是一家研发驱动型生物医药企业，致力于全球创新药物（First-in-class/ Best-in-class）探索、研发以及商业化。
    详情请点击公司官方网站：**************************/

Dizal Pharma
On Nov. 27th, 2017, through a joint venture between AstraZeneca and China Advanced Manufacturing Fund, Dizal Pharma was co-constructed as a world-leading innovative bio-pharmaceutical enterprise. As a new, unique mode of cooperation between SDIC Fund Management Company Ltd. and worldwide privileged research resources in the field of biological pharmacy, Dizal Pharma can not only accelerate the launch and listing of global new drugs in China, bring Chinese patients access to the latest drugs found across the world at once and thus raise the clinical benefits of patients; At the same time, we also take advantages of the global privileged innovative resources, increase China’s core competitive power in the innovation of new drugs, step in the leading branch of international research and development of new drugs and push China into the role of causing both huge and powerful influence in pharmacy industry.
As a new-style joint venture company, besides the project of the transfer of AstraZeneca’s patents, Dizal Pharma also develops the innovation and creation of global First-in-Class drugs.
The R&D (Research and Development) team of Dizal Pharma was AstraZeneca Asia and Emerging Market Research Center. As one of AstraZeneca’s first four R&D centers across the world, it dedicated to analyze the potential scientific mechanism of those most common diseases in Asia and fulfill the particular medical needs of Asian patients. It was one of the few R&D centers established by transnational pharmacy enterprises in China which had the ability to actually research, develop and produce micro-molecular new drugs, the ability to develop produce new drugs independently and completely, and the first-class medical platform in the world.